Novel sterically hindered cannabinoid CB1 receptor ligands

• Published in: Bioorganic & medicinal chemistry 2008-08, Vol.16 (15), p.7510-7515
• Main Authors: URBANI, Paolo, GRAZIA CASCIO, Maria, RAMUNNO, Anna, BISOGNO, Tiziana, SATURNINO, Carmela, DI MARZO, Vincenzo
• Format: Article
• Language: English
• Subjects: Acetamides - chemistry; Acetamides - pharmacology; Animals; Biological and medical sciences; Cell Line, Tumor; Ligands; Medical sciences; Mice; Miscellaneous; Molecular Structure; Neuropharmacology; Neurotransmitters. Neurotransmission. Receptors; Pharmacology. Drug treatments; Receptor, Cannabinoid, CB1 - chemistry; Receptor, Cannabinoid, CB1 - metabolism; Structure-Activity Relationship
• ISSN: 0968-0896; 1464-3391
• DOI: 10.1016/j.bmc.2008.06.001

In the present study, 11 novel N-(3,3-diphenyl)propyl-2,2-diphenylacetamide derivatives (4a-d and 9a-g) and six triphenylacetamides (10a-c and 11a-c) were synthesized and tested as ligands of cannabinoid CB(1) and CB(2) receptors. All compounds exhibited affinity for CB(1) and CB(2) receptors. Four compounds (4b, 9a, 9b, and 11a) showed selectivity for CB(1) versus CB(2) receptors, although only the N-(3,3-diphenyl)propyl-2,2-diphenylacetamide (4b) can be considered a potent CB(1) ligand (K(i)=58 nM). It was 140-fold selective over CB(2) receptors (K(i)=7800 nM) and behaved as an inverse agonist by stimulating forskolin-induced cAMP formation in mouse N18TG2 neuroblastoma cells. This compound is the first of a novel class of tetraphenyl CB(1) ligands that, in view of its easy synthesis and high affinity for CB(1) receptors and despite its sterical hindrance, will be useful for the design of new blockers of this therapeutically exploitable receptor type.